Groupement Interrégional de Recherche Clinique et d'Innovation Est Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2020
NCT04570085
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Groupement Interrégional de Recherche Clinique et d'Innovation | Groupement Interrégional de Recherche Clinique et d'Innovation Est

Active Ingredients

Drugs in Phase 3 Trials (1)

caffeine (1 trial)

Drugs in Other Trials (1)

ginseng (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2